Jazz Pharmaceuticals (JAZZ) Intangibles (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Intangibles of $4.2 billion for Q1 2026, down 10.9% year-over-year from $4.7 billion in Q1 2025, and down 5.1% quarter-over-quarter from $4.4 billion in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Intangibles (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Intangibles history runs 17 years deep, the most recent figure standing at $4.2 billion for Q1 2026.
- In Q1 2026, Intangibles fell 10.9% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (down 10.9% YoY), while the FY2025 annual figure was $4.4 billion, down 6.86% from the prior year.
- Intangibles for Q1 2026 stood at $4.2 billion, down from $4.4 billion in the prior quarter.
- The five-year high for Intangibles was $6.8 billion in Q1 2022, with the low at $752.5 million in Q4 2023.
- The 5-year median for Intangibles is $5.1 billion (2024), against an average of $5.0 billion.
- The sharpest annual moves came in 2022 and 2023: Intangibles jumped 556939.4% in 2022, then plunged 87.01% in 2023.
- Jazz Pharmaceuticals' Intangibles stood at $5.8 billion in 2022, then slumped by 87.01% to $752.5 million in 2023, then jumped by 531.99% to $4.8 billion in 2024, then decreased by 6.86% to $4.4 billion in 2025, then slipped by 5.1% to $4.2 billion in 2026.
- Business Quant data shows JAZZ's Intangibles at $4.2 billion in Q1 2026, $4.4 billion in Q4 2025, and $4.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 4.03 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Bn |
| Mar 31, 2026 | 4.20 Bn |
| Dec 31, 2025 | 4.43 Bn |
| Sep 30, 2025 | 4.57 Bn |
| Jun 30, 2025 | 4.77 Bn |
| Mar 31, 2025 | 4.72 Bn |
| Dec 31, 2024 | 4.76 Bn |
| Sep 30, 2024 | 5.14 Bn |
| Jun 30, 2024 | 5.08 Bn |
| Mar 31, 2024 | 5.24 Bn |
| Dec 31, 2023 | 752.50 Mn |
| Sep 30, 2023 | 5.42 Bn |
| Jun 30, 2023 | 5.71 Bn |
| Mar 31, 2023 | 5.76 Bn |
| Dec 31, 2022 | 5.79 Bn |
| Sep 30, 2022 | 5.57 Bn |
| Jun 30, 2022 | 6.24 Bn |
| Mar 31, 2022 | 6.78 Bn |
| Dec 31, 2021 | 7.15 Bn |
| Sep 30, 2021 | 1.00 Mn |